|
1
|
Messerschmitt PJ, Garcia RM, Abdul-Karim
FW, Greenfield EM and Getty PJ: Osteosarcoma. J Am Acad Orthop
Surg. 17:515–527. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Schiller AL: Orthopaedic pathology. Semin
Diagn Pathol. 28:1–3. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Siegel RL, Miller KD and Jemal A: Cancer
statistics, 2015. CA Cancer J Clin. 65:5–29. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Mendoza SM, Konishi T and Miller CW:
Integration of SV40 in human osteosarcoma DNA. Oncogene.
17:2457–2462. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Mazabraud A: Experimental production of
bone sarcomas in the rabbit by a single local injection of
beryllium. Bull Cancer. 62:49–58. 1975.(In French). PubMed/NCBI
|
|
6
|
Miller BJ, Cram P, Lynch CF and Buckwalter
JA: Risk factors for metastatic disease at presentation with
osteosarcoma: An analysis of the SEER database. J Bone Joint Surg
Am. 95:e892013. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Fabbri A, Motta E, Ferrari S, Longhi C,
Marchi E, Bacci G, Figus E and Marchesini G: High-dose methotrexate
treatment and liver function in patients with osteosarcoma. J
Intern Med. 236:209–214. 1994. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Lin F, Wang Q, Yu W, Tang L, Zheng S, Sun
Y, Shen Z, Yao Y and Dong Y: Clinical analysis of Chinese limb
osteosarcoma patients treated by two combinations of methotrexate,
cisplatin, doxorubicin and ifosfamide. Asia-Pac J Clin Oncol.
7:270–275. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Bacci G and Lari S: Adjuvant and
neoadjuvant chemotherapy in osteosarcoma. Chir Organi Mov.
86:253–268. 2001.(Article in English, Italian). PubMed/NCBI
|
|
10
|
Biermann JS and Baker LH: The future of
sarcoma treatment. Semin Oncol. 24:592–597. 1997.PubMed/NCBI
|
|
11
|
La Quaglia MP: Osteosarcoma. Specific
tumor management and results. Chest Surg Clin N Am. 8:77–95.
1998.PubMed/NCBI
|
|
12
|
Yue Z, Guan X, Chao R, Huang C, Li D, Yang
P, Liu S, Hasegawa T, Guo J and Li M: Diallyl disulfide induces
apoptosis and autophagy in human osteosarcoma MG-63 cells through
the PI3K/Akt/mTOR pathway. Molecules. 24:26652019. View Article : Google Scholar
|
|
13
|
Kurowska P, Mlyczyńska E, Dawid M,
Opydo-Chanek M, Dupont J and Rak A: In vitro effects of vaspin on
porcine granulosa cell proliferation, cell cycle progression, and
apoptosis by activation of GRP78 receptor and several kinase
signaling pathways including MAP3/1, AKT, and STAT3. Int J Mol Sci.
20:58162019. View Article : Google Scholar
|
|
14
|
Li B, Zhou P, Xu K, Chen T, Jiao J, Wei H,
Yang X, Xu W, Wan W and Xiao J: Metformin induces cell cycle
arrest, apoptosis and autophagy through ROS/JNK signaling pathway
in human osteosarcoma. Int J Biol Sci. 16:74–84. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Duronio RJ and Xiong Y: Signaling pathways
that control cell proliferation. Cold Spring Harb Perspect Biol.
5:a0089042013. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Cavallaro G, Cucina A, Coluccia P,
Petramala L, Cotesta D, Polistena A, Zinnamosca L, Letizia C,
Rosato L, Cavallaro A and De Toma G: Role of growth factors on
human parathyroid adenoma cell proliferation. World J Surg.
34:48–54. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Kaldis P and Pagano M: Wnt signaling in
mitosis. Dev Cell. 17:749–750. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Huang Q, Shi SY, Ji HB and Xing SX: LncRNA
BE503655 inhibits osteosarcoma cell proliferation,
invasion/migration via Wnt/β-catenin pathway. Biosci Rep.
39:BSR201822002019. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Keremu A, Maimaiti X, Aimaiti A, Yushan M,
Alike Y, Yilihamu Y and Yusufu A: NRSN2 promotes osteosarcoma cell
proliferation and growth through PI3K/Akt/MTOR and Wnt/β-catenin
signaling. Am J Cancer Res. 7:565–573. 2017.PubMed/NCBI
|
|
20
|
Zhao H, Hou W, Tao J, Zhao Y, Wan G, Ma C
and Xu H: Upregulation of lncRNA HNF1A-AS1 promotes cell
proliferation and metastasis in osteosarcoma through activation of
the Wnt/β-catenin signaling pathway. Am J Transl Res. 8:3503–3512.
2016.PubMed/NCBI
|
|
21
|
Jin H, Luo S, Wang Y, Liu C, Piao Z, Xu M,
Guan W, Li Q, Zou H, Tan QY, et al: miR-135b stimulates
osteosarcoma recurrence and lung metastasis via Notch and
Wnt/β-catenin signaling. Mol Ther Nucleic Acids. 8:111–122. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Fu X, Duanmu J, Li T and Jiang Q: A
7-lncRNA signature associated with the prognosis of colon
adenocarcinoma. PeerJ. 8:e88772020. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Wang Y, Huang Y, Xiang P and Tian W:
LncRNA expression and implication in osteosarcoma: A systematic
review and meta-analysis. Onco Targets Ther. 10:5355–5361. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Xie C, Chen B, Wu B, Guo J and Cao Y:
LncRNA TUG1 promotes cell proliferation and suppresses apoptosis in
osteosarcoma by regulating miR-212-3p/FOXA1 axis. Biomed
Pharmacother. 97:1645–1653. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Ju L, Zhou YM and Yang GS: Up-regulation
of long non-coding RNA BCAR4 predicts a poor prognosis in patients
with osteosarcoma, and promotes cell invasion and metastasis. Eur
Rev Med Pharmacol Sci. 20:4445–4451. 2016.PubMed/NCBI
|
|
26
|
Kong D and Wang Y: Knockdown of lncRNA
HULC inhibits proliferation, migration, invasion, and promotes
apoptosis by sponging miR-122 in osteosarcoma. J Cell Biochem.
119:1050–1061. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Jiang N, Wang X, Xie X, Liao Y, Liu N, Liu
J, Miao N, Shen J and Peng T: lncRNA DANCR promotes tumor
progression and cancer stemness features in osteosarcoma by
upregulating AXL via miR-33a-5p inhibition. Cancer Lett. 405:46–55.
2017. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Zhang CL, Zhu KP and Ma XL: Antisense
lncRNA FOXC2-AS1 promotes doxorubicin resistance in osteosarcoma by
increasing the expression of FOXC2. Cancer Lett. 396:66–75. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Wu Q, Xiang S, Ma J, Hui P, Wang T, Meng
W, Shi M and Wang Y: Long non-coding RNA CASC15 regulates gastric
cancer cell proliferation, migration and epithelial mesenchymal
transition by targeting CDKN1A and ZEB1. Mol Oncol. 12:799–813.
2018. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Fernando TR, Contreras JR, Zampini M,
Rodriguez-Malave NI, Alberti MO, Anguiano J, Tran TM, Palanichamy
JK, Gajeton J, Ung NM, et al: The lncRNA CASC15 regulates SOX4
expression in RUNX1-rearranged acute leukemia. Mol Cancer.
16:1262017. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Jing N, Huang T, Guo H, Yang J, Li M, Chen
Z and Zhang Y: LncRNA CASC15 promotes colon cancer cell
proliferation and metastasis by regulating the
miR-4310/LGR5/Wnt/β-catenin signaling pathway. Mol Med Rep.
18:2269–2276. 2018.PubMed/NCBI
|
|
32
|
Zhang H, Wang J, Ren T, Huang Y, Yu Y,
Chen C, Huang Q and Guo W: LncRNA CASC15 is upregulated in
osteosarcoma plasma exosomes and CASC15 knockdown inhibits
osteosarcoma progression by regulating miR-338-3p/RAB14 axis. Onco
Targets Ther. 13:12055–12066. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Hurst DR, Edmonds MD, Scott GK, Benz CC,
Vaidya KS and Welch DR: Breast cancer metastasis suppressor 1
up-regulates miR-146, which suppresses breast cancer metastasis.
Cancer Res. 69:1279–1283. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Wang B, Xu W, Cai Y, Guo C, Zhou G and
Yuan C: CASC15: A tumor-associated long non-coding RNA. Curr Pharm
Des. 27:127–134. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Zhang J, Cai H, Sun L, Zhan P, Chen M,
Zhang F, Ran Y and Wan J: LGR5, a novel functional glioma stem cell
marker, promotes EMT by activating the Wnt/β-catenin pathway and
predicts poor survival of glioma patients. J Exp Clin Cancer Res.
37:2252018. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Hay ED: An overview of
epithelio-mesenchymal transformation. Acta Anat (Basel). 154:8–20.
1995. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Li P, Pan X, Zheng Z, Sun Y, Han Y and
Dong J: LINC00271 inhibits epithelial-mesenchymal transition of
papillary thyroid cancer cells by downregulating trefoil factor 3
expression. Aging Pathobiol Ther. 2:78–85. 2020. View Article : Google Scholar
|
|
39
|
Thiery JP and Sleeman JP: Complex networks
orchestrate epithelial-mesenchymal transitions. Nat Rev Mol Cell
Biol. 7:131–142. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Thiery JP, Acloque H, Huang RY and Nieto
MA: Epithelial-mesenchymal transitions in development and disease.
Cell. 139:871–890. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Acloque H, Adams MS, Fishwick K,
Bronner-Fraser M and Nieto MA: Epithelial-mesenchymal transitions:
The importance of changing cell state in development and disease. J
Clin Invest. 119:1438–1449. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Kalluri R and Weinberg RA: The basics of
epithelial-mesenchymal transition. J Clin Invest. 119:1420–1428.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Li A and Machesky LM: Melanoblasts on the
move: Rac1 sets the pace. Small GTPases. 3:115–119. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Jayanthi P, Varun BR and Selvaraj J:
Epithelial-mesenchymal transition in oral squamous cell carcinoma:
An insight into molecular mechanisms and clinical implications. J
Oral Maxillofac Pathol. 24:1892020. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Liu X, Qiao B, Zhao T, Hu F, Lam AK and
Tao Q: Sox2 promotes tumor aggressiveness and
epithelial-mesenchymal transition in tongue squamous cell
carcinoma. Int J Mol Med. 42:1418–1426. 2018.PubMed/NCBI
|
|
46
|
Weber CE, Li NY, Wai PY and Kuo PC:
Epithelial-mesenchymal transition, TGF-β, and osteopontin in wound
healing and tissue remodeling after injury. J Burn Care Res.
33:311–318. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Sharma RP and Chopra VL: Effect of the
Wingless (wg1) mutation on wing and haltere development in
Drosophila melanogaster. Dev Biol. 48:461–465. 1976. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Yamaguchi TP: Heads or tails: Wnts and
anterior-posterior patterning. Curr Biol. 11:R713–R724. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Nusse R and Varmus HE: Many tumors induced
by the mouse mammary tumor virus contain a provirus integrated in
the same region of the host genome. Cell. 31:99–109. 1982.
View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Shetti D, Zhang B, Fan C, Mo C, Lee BH and
Wei K: Low dose of paclitaxel combined with XAV939 attenuates
metastasis, angiogenesis and growth in breast cancer by suppressing
Wnt signaling. Cells. 8:8922019. View Article : Google Scholar
|
|
51
|
Saito-Diaz K, Chen TW, Wang X, Thorne CA,
Wallace HA, Page-McCaw A and Lee E: The way Wnt works: Components
and mechanism. Growth Factors. 31:1–31. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
52
|
de Sousa EM, Vermeulen L, Richel D and
Medema JP: Targeting Wnt signaling in colon cancer stem cells. Clin
Cancer Res. 17:647–653. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Jubb AM, Chalasani S, Frantz GD, Smits R,
Grabsch HI, Kavi V, Maughan NJ, Hillan KJ, Quirke P and Koeppen H:
Achaete-scute like 2 (ascl2) is a target of Wnt signalling and is
upregulated in intestinal neoplasia. Oncogene. 25:3445–3457. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
54
|
Rashid MS, Mazur T, Ji W, Liu ST and
Taylor WR: Analysis of the role of GSK3 in the mitotic checkpoint.
Sci Rep. 8:142592018. View Article : Google Scholar : PubMed/NCBI
|
|
55
|
Xiao C, Wu CH and Hu HZ: LncRNA UCA1
promotes epithelial-mesenchymal transition (EMT) of breast cancer
cells via enhancing Wnt/beta-catenin signaling pathway. Euro Rev
Med Pharmacol Sci. 20:2819–2824. 2016.
|
|
56
|
Yue B, Liu C, Sun H, Liu M, Song C, Cui R,
Qiu S and Zhong M: A positive feed-forward loop between
LncRNA-CYTOR and Wnt/β-Catenin signaling promotes metastasis of
colon cancer. Mol Ther. 26:1287–1298. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
57
|
Yu J, Han Z, Sun Z, Wang Y, Zheng M and
Song C: LncRNA SLCO4A1-AS1 facilitates growth and metastasis of
colorectal cancer through β-catenin-dependent Wnt pathway. J Exp
Clin Cancer Res. 37:2222018. View Article : Google Scholar : PubMed/NCBI
|
